Immunic to Host Virtual Celiac Disease R&D Day to Highlight Current Pathways for Drug Development and Unmet Medical Need - Conference Call and Webcast to be Held Today

Immunic to Host Virtual Celiac Disease R&D

Day to Highlight Current Pathways for Drug Development and Unmet Medical Need

Conference Call and Webcast to be Held Today, February 9, 2023, at 11:00 am ET -

February 9, 2023 - Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline

of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced that its Celiac

Disease R&D Webcast will take place today, February 9, 2023 from 11:00 am to 1:00 pm ET.

Management of Immunic, including Daniel Vitt,

Ph.D., Chief Executive Officer and President; Andreas Muehler, M.D., M.B.A., Chief Medical Officer; and Hella Kohlhof, Ph.D., Chief Scientific

Officer, will be joined by renowned key opinion leaders to discuss the dynamics of this multifactorial, complex autoimmune disease, immune

stimulation and its connection to clinical symptoms, the role of the epithelial barrier in the pathogenesis of the disease, current and

potential treatment options, and the continued unmet medical need for effective therapeutics, which is driving an increased focus within

Featured key opinion leaders will be:

"We look forward to hosting this deep-dive

discussion, focused on the current challenges of treating celiac disease with two, such renowned thought leaders as Drs. Murray and Schumann,"

stated Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic. "The only current treatment option for celiac patients

is life-long, strict adherence to a gluten-free diet, yet many of those who follow such a protocol still experience persistent disease

activity, leading to a significant unmet need for this patient population. With the participation of these two key opinion leaders, this

event will help to illuminate the most important issues being considered by the industry, today. Immunic, itself, remains committed to

its research in this area and we currently expect to provide initial results from the Part C portion of our ongoing phase 1 clinical trial

of IMU-856 in celiac disease patients, in mid-2023."

The Celiac Disease R&D Day webcast will be

held virtually via Zoom. To participate, please register in advance at: https://imux.zoom.us/webinar/register/WN_wI-01YeJSbe4XRTFO1PLQw.

Registrants will receive a confirmation email

containing a link for online participation or a telephone number for dial in access.

An archived replay of the webcast will be available

approximately one hour after completion on Immunic's website at: ir.imux.com/events-and-presentations.

Celiac disease is a multifactorial, complex autoimmune

disease caused by an inappropriate immune reaction against a degradation product of gluten in genetically susceptible individuals. It

is characterized by small intestinal epithelial injury, elevated intestinal permeability, and nutrient malabsorption. Celiac disease causes

debilitating signs and symptoms of malabsorption such as diarrhea, steatorrhea, fatigue, weight

loss, anemia, osteopenia, and can lead to serious complications such as enteropathy-associated

T-cell lymphoma. In children, nutrient malabsorption can affect growth and development, in addition to causing the symptoms seen in adults.

There is currently no known cure or treatment for celiac disease and patients must adhere to a strict, life-long gluten-free diet which

can help manage symptoms and avoid disease flareups. Celiac disease is estimated to affect 1 in 100 people, worldwide. In the U.S., alone,

it is estimated that 2.5 million people are undiagnosed and are, therefore, at risk for long-term health complications.

Immunic, Inc. (Nasdaq:

IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic

inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, vidofludimus

calcium (IMU-838), a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme

DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis. IMU-935,

a selective inverse agonist of the transcription factor ROR /ROR t, is targeted for development in psoriasis, and castration-resistant

prostate cancer. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving

bowel barrier dysfunction and regeneration of bowel epithelium. For further information, please visit: www.imux.com.

Statement Regarding Forward-Looking Statements

This press release contains "forward-looking

statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities

Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy,

future operations, future financial position, future revenue, projected expenses, sufficiency of cash, expected timing and results of

clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but

are not limited to, statements relating to Immunic's three development programs and the targeted diseases; the potential for IMU-856

to safely and effectively target diseases; interpretation of preclinical and clinical data for IMU-856 and potential effects; the timing

of current and future clinical trials and anticipated clinical milestones; the nature, strategy and focus of the company and further updates

with respect thereto; and the development and commercial potential of any product candidates of the company. Immunic may not actually

achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you

should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations

and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking

statements as a result of many factors, including, without limitation, the COVID-19 pandemic, increasing inflation, impacts of the Ukraine

- Russia conflict on clinical trials, risks and uncertainties associated with the ability to project future cash utilization and

reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources

to meet business objectives and operational requirements, the fact that the results of earlier preclinical studies and clinical trials

may not be predictive of future clinical trial results, the protection and market exclusivity provided by Immunic's intellectual

property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological

changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned "Risk

Factors," in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the SEC on February

24, 2022, and in the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available

online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this

release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that

exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based

on any or all the contents of this press release.

Head of Investor Relations and Communications

Rx Communications Group